AGENDA CONNECTICUT MEDICAL EXAMINING BOARD Tuesday, September 15, 2020 at 1:30 PM

Department of Public Health 410 Capitol Avenue, Hartford Connecticut

CALL TO ORDER

I. APPROVAL OF MINUTES

July 21, 2020

II. OPEN FORUM

III. UPDATES

- A. Chair Updates
- B. DPH Updates

IV. NEW BUSINESS

- A. Review of License Reinstatement Application
 - Presented by Celeste Dowdell, License and Applications Analyst
 - Onikepe Adegbola, MD
 - Sarita Mallya, MD

V. OFFICE OF LEGAL COMPLIANCE

- A. Bryan Boffi, M.D.- Petition No. 2016-1045
 - Presentation of Consent Order Modification Presented by Diane Wilan, Staff Attorney, DPH
- B. Glen Rosenfeld, M.D.- Petition No. 2019-44

Presentation of Consent Order Modification - Presented by Linda Fazzina, Staff Attorney, DPH

ADJOURN

This meeting will be held by video conference at the following link

Connecticut Medical Examining Board via Microsoft Teams

+1 860-840-2075 - Conference ID: 203 841 514#

The following minutes are draft minutes which are subject to revision and which have not yet been adopted by the Board.

CONNECTICUT MEDICAL EXAMINING BOARD MINUTES of July 21, 2020

The Connecticut Medical Examining Board held a meeting on Tuesday, July 21, 2020 by video conference.

BOARD MEMBERS PRESENT: Kathryn Emmett, Esq., Chairperson

Allyson Duffy, MD Marie C. Eugene, DO Robert Green, MD Michele Jacklin Marilyn Katz, MD Shawn London, MD Edward McAnaney, Esq.

Jean Rexford
Daniel Rissi, MD
Harold Sauer. MD
David Schwindt. MD
C. Steven Wolf, MD
Andrew Yuan, DO
Peter Zeman, MD

BOARD MEMBERS ABSENT: Brimal Patel, MD

Edward McAnaney, Esq. Shawn London, MD

Ms. Emmett called the meeting to order at 1:30 p.m.

I. MINUTES

The draft minutes of the June 16, 2020 meeting were reviewed. Ms. Rexford made a motion, seconded by Dr. Sauer to approve the minutes. The motion passed with all in favor except Dr. Duffy who abstained.

II. OPEN FORUM

None

III. UPDATES

A. Chair Updates

- Monthly tracking of pending cases.
- Hearing assignments.

B. <u>Department of Public Health</u>

None

Ms. Jacklin and Dr. Green joined the meeting at 1:35 p.m.

IV. NEW BUSINESS

A. <u>Joint Request to modify Memorandum of Decision - Kakara Gyambibi, MD - Petition No. 2017-16</u>0 Assistant Attorney General Daniel Shapiro was present to provide counsel to the Board. Attorney Daniel Csuka was present on behalf of Dr. Gyambibi. Staff Attorney David Tilles was present for the Department of Public Health.

Dr. Wolf made a motion, seconded by Ms. Rexford to grant the request to add language to the Memorandum of Decision. The motion passed unanimously.

V. OFFICE OF LEGAL COMPLIANCE

A. Gayle Klein, M.D.- Petition No. 2018-695

Staff Attorney David Tilles, Department of Public Health, presented a Modified Consent Order in this matter. Respondent was not present.

Dr. Wolf made a motion, seconded by Ms. Rexford to approve modified language in the Consent Order. The motion passed unanimously.

B. Ronald · Buckman, M.D.- Petition No. 2018-1317

Staff Attorney David Tilles, Department of Public Health, presented a Consent Order in this matter.

Attorney Joan Feldman was present on behalf of respondent.

Dr. Rissi made a motion, seconded by Dr, Zeman, to approve the Consent Order which imposes a reprimand, probation for 12 months and a \$4000.00 civil penalty. The motion to table passed with all in favor except Dr. Green who abstained.

C. Kenneth Kramer, M.D.- Petition No. 2019-1368

Staff Attorney Brittany Allen, Department of Public Health, presented a Consent Order in this matter. Respondent was not present.

Dr. Wolf made a motion, seconded by Dr, Sauerr, to approve the Consent Order which imposes a reprimand. The motion to table passed with all in favor except Dr. Katz who abstained.

VI. ADJOURNMENT

As there was no further business, the meeting was adjourned at 1:58 p.m.

Respectfully submitted, Kathryn Emmett, Esq., Chairperson TO:

Connecticut Medical Examining Board

FROM:

Celeste Dowdell

Licensing Applications Analyst

Practitioner Licensing and Investigations Section

RE:

Onikepe Adegbola, MD

Dr. Adegbola is an applicant for Connecticut physician licensure reinstatement. Dr. Adegbola meets all requirements for reinstatement except she has been out of active practice.

Applicants who have been out of active clinical practice longer than six (6) months are reviewed by the Connecticut Medical Examining Board. The CMEB could require applicants who have been out of active clinical practice for longer than two years to complete the Federation of State Medical Board's Special Purpose Examination (SPEX).

Please accept this as a summary of the documentation submitted in support of Dr. Adegbola's application.

Medical Education: College of Medicine, University of Lagos, Nigeria- 1995

United States Medical Licensing Examination: Parts 1-3 completed and passed

Post Graduate Training Completed:

06/26/1997-08/15/1997: Howard University- Transitional

07/01/98-06/30/00: New York Presbyterian Hospital- Pathology Resident

07/01/05-06/30/07: Hospital of the University of Pennsylvania- Nuclear Medicine Resident

Dr. Adegbola previously held a license in Pennsylvania. There is no history of discipline against this license.

CT license issued 6/1/2007, expired 6/30/2008

Dr. Adegbola is board certified in Nuclear Medicine

Activities since License expired:

Statements attached

Connecticut Department of Public Health Physician Licensure 410 Capitol Ave., MS# 12APP P.O. Box 340308 Hartford, CT 06134-0308 Fax: (860) 707-1931 8/13/2020

To Whom It May Concern:

REINSTATEMENT OF LAPSED LICENSE 045473

I am writing this statement regarding my clinical activities after I completed residency in 2007. After completion of residency, I did no clinical work, or had any clinical positions. I worked in the pharmaceutical industry until 2015 when I was laid off from Quest Diagnostics. Since 2015 I have been a stay at home mother to my triplets as well as founding and running a biotect company and a food company pat time.

Sincerely,

Onikepe Adegbola, MD PhD

2605 BRIDLE PATH ROAD • EAST NORRITON, PA 19403
PHONE 443-345-7029 • E-MAIL OADEGBOLA@GMAIL.COM

ONIKEPE ADEGBOLA, MD PhD

PROFESSIONAL PROFILE

- Physician-scientist with research background in oncology, and clinical background in anatomic and laboratory pathology and molecular imaging
- Expertise in biomarker strategy in drug development
- Experienced in clinical trial design and execution
- Clinical Development, Medical Affairs, and Technology Assessment expertise in Pharma and Medical Devices
- Expertise in medical strategy for product commercialization, launch and lifecycle management. Extensive experience in Medical Affairs activities from opportunity identification, product development and commercialization to launch and lifecycle management
- Strong interpersonal, influencing, presentation, and communications skills.
 Experience leading cross-functional teams including R&D, Safety,
 Commercial, Regulatory, Legal, Policy, HEOR, Patient Advocacy and
 Reimbursement in a highly matrixed organization.
- Consistent track record of successfully managing people and projects in various roles in the pharmaceutical and medical device industry
- Board-certified nuclear medicine physician. Connecticut Physician License, 2007-present, Pennsylvania Physician License, 2009-present
- Clinical training in anatomic pathology and clinical pathology
- Research training (PhD) in pathobiology (concentration in cancer biology)

AREAS OF EXPERTISE

molecular and cellular biology, immunobiology, biomarker discovery and strategy, imaging, translational medicine, oncology, anatomic and clinical pathology, clinical development, commercialization, Medical Affairs, pharmaceuticals, medical device

EDUCATION

The Johns Hopkins University School of Medicine, Baltimore

 PhD, Pathobiology (concentration: cancer biology), 2001-2005. Thesis: Identification and Characterization of an Interaction between pp32 and the Retinoblasoma Protein (Rb)

University Of Edinburgh, Scotland

Clinical Oncology Elective, 1995

University of Lagos, Nigeria

MD, 1988 - 1995

GRE General Test, April 2000, score - 2340

- Verbal 800 (99th percentile)
- Analytical 800 (99th percentile)
- Quantitative 740 (85th percentile)

PROFESSIONAL EXPERIENCE

Founder. Casa de Sante, 2019- Present

CEO, A'as, Inc, 2016 -- 2019

• Founder & CEO, responsible for fundraising. Obtained funding through successful grant applications for SBIR and State of Maryland grants.

Global Head, Scientific Affairs, Clinical Trials, Quest Diagnostics, May 2013 - September 2015

- Led the scientific affairs function that has both commercial and operational responsibilities
- Recruited and managed a team of 20, including 5 PhD level scientists in the scientific affairs team who are customer facing, laboratory medicine specialists that support the sales team in developing new commercial opportunities (including companion dx support)
- Supported business development and due diligence activities; developed relationships with key Pharma development personnel in order to develop a customer base for our biomarker and CDx efforts
- As interim head of Quality, ensured timely clinical trial study setup (competitive with other central labs and CROs) and eliminated errors / quality failures by 50%
- Built a network across Quest Diagnostics clinical franchises and Scientific
 and Innovation teams to ensure that Clinical Trials is always able to bring
 customers the most complete offering from Quest, including providing
 scientific input and strategy into clinical trial protocols; moved Quest from
 bottom third to top CRO in scientific expertise based on Pharma customer
 survey
- Ensured that the commercial and PM teams had adequate technical and scientific support, including scientific affairs plans for major customers, articles, presentations and a quarterly newsletter
- Maintained up to date knowledge of Good Laboratory Practice (GLP), Good Clinical Practice (GCP), Clinical Laboratory Improvement Act (CLIA) regulations

Chief Medical Officer, Molecular Imaging, Executive Medical Director, GE Healthcare, December 2010 – April 2013

- Lead the clinical evaluation and validation of new products (NPIs) as the leader of the clinical research team
- Lead the generation of clinical strategy and design for NPIs
- Lead and oversee GE-sponsored clinical trials, act as medical monitor for GE-sponsored trials
- Lead the design and execution of clinical studies confirming the performance of NPIs relative to specific unmet medical needs
- Build and maintain relationships with KOLs, medical societies and advocacy groups to support GE strategy and clinical adoption of products
- Act as a medical contact for the FDA and other government and regulatory agencies concerning clinical issues for MI products
- Manage clinical studies, working closely with medical facilities, academia, and CROs
- Provide subject matter expertise for patient safety and in medical risk assessments within the Post-Market Safety Review Board.
- Participate on the NPI review committee for Molecular Imaging (MI) that reviews clinical trials for merit of progression to next stage of development
- Lead publication strategy. Coordinate publication and regulatory submissions that include clinical data in support of Regulatory Affairs
- Lead and participate in medical advisory boards
- Provide direction and leadership in HEOR and CER to develop customer value propositions for new and existing products
- Support due diligence for acquisitions and intellectual property licensing

Medical Director, US Medical Affairs, Diagnostic Imaging Bayer HealthCare Pharmaceuticals, September 2008 – November 2010

- Brand Medical Lead for Magnevist, the market leading MRI contrast agent. Responsible for development and execution of medical strategy to support and grow Magnevist. As medical/scientific expert led, directed or supported activities of MSL, HEOR, CME, ISS, Commercial, (Marketing, Sales, Business Development), R&D, Safety, Regulatory and Legal functions
- Member of Global Launch team for Florbetaben, an amyloid imaging agent for Alzheimer's Dementia. Responsible for US medical launch strategy and activities, working closely with R&D and Commercial teams for successful registration and launch plans including marketing and commercial strategy, market research, competitive intelligence, training programs, speaker training, advisory boards, investigator meetings, publication planning and building/maintaining relationships with neurology, psychiatry and radiology KOLs, professional organizations and patient advocacy groups
- Clinical Research Physician (Medical Expert) for Phase III/IV clinical trials

Onikepe Adegbola, MD PhD

- Responsible for strategy and execution of Medical Affairs Plans, including publications, advisory boards, speaker training, CME, ISS, and Medical Information for assigned brands. Provided strategic medical input to Commercial Brand Plans
- Consultant to Commercial team on relevant acquisitions, joint ventures or other strategic partnerships for assigned brands and molecular imaging
- Developed ISS strategy and identified gaps. Evaluated investigator-initiated studies and grant requests and developed publication strategy
- Supported Public Relations and Corporate Communications to publicize relevant product information. Reviewed and edited press releases
- Identified, built and maintained relationships with KOLs and key external customers including professional organizations and advocacy groups
- Represented the Company on medical/scientific aspects of brand-specific interactions, communications and presentations with internal and external stakeholders including the FDA, KOLs, HCPs, GPOs, and customers
- Accountable for the accuracy of medical/scientific and promotional materials and other company communications for Magnevist, Eovist and Florbetaben through the medical legal regulatory review (MLR) process
- Medical Lead for cross functional team (Safety, Regulatory, R&D, Commercial, Legal, PR) on response to product safety issue (NSF)

Imaging Project Leader, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals Corporation, July 2007 - August 2008

- Proactively identified relevant imaging methodologies and innovative applications to accelerate progression of oncology product candidates from preclinical to Proof of Concept (POC) and Phase I-III
- Developed the imaging biomarker strategy, including translational imaging, from preclinical to clinical development (Phase I-III) for multiple product candidates and global clinical trials (including 4 of 5 high priority oncology projects)
- Successfully integrated laboratory and imaging biomarker strategy for multiple product candidates and global clinical trials
- Integrated imaging and laboratory biomarker data and presented to clinical teams and clinical development leadership
- Evaluated and interpreted imaging biomarker data in trials and made strategic recommendations related to protocol objectives

Onikepe Adegbola, MD PhD

- Oversaw and managed imaging budget for clinical trials
- Successfully led and managed global trials with a team of study managers, CROs, line functions and academic institutions. Ensured execution excellence of imaging strategy in oncology global trials in a timely manner within resources and budget
- Member of the ICT, IPT and Clinical Submission teams
- Authored the imaging biomarker portions of the Translation Medicine Plan & POC, Clinical Development Plan, Clinical Study Protocols, Investigator Brochure and Clinical Study Reports
- Authored biomarker sections/reports for INDs, Investigator Brochures, FDA briefing books, and submission documents
- Developed and authored SOPs to ensure standardization of molecular imaging techniques and data in multi-center global trials
- Identified appropriate CROs, clinical trial sites and external consultants and assisted in writing contracts and budgets

Nuclear Medicine Fellow, University of Pennsylvania School of Medicine, July 2005 - June 2007

- Comprehensive experience in all aspects of Nuclear Medicine and molecular imaging (PET/CT), including both diagnostic and therapeutic applications of radionuclides
- Prepared and delivered presentations and lectures
- Performed preclinical PET research in mice using lymphoma xenografts

PhD candidate, The Johns Hopkins University School of Medicine, Baltimore, July 2001- June 2005

 PhD, Pathobiology (concentration: cancer biology). Thesis: Identification and Characterization of an Interaction between pp32 and the Retinoblasoma Protein (Rb)

Postdoctoral Fellow, University of California San Francisco, August 2000 - July 2001

- Investigated gene expression and cell biology of yeast with microarray and molecular biology assays
- Annotated the Candida genome using computational biology

Pathology Resident, Columbia University College Of Physicians and Surgeons, July 1998 - July 2000

Onikepe Adegbola, MD PhD

- Clinical training in anatomic and clinical pathology, including molecular diagnostics and molecular pathology, hematopathology, immunoserology transfusion medicine, plasmapheresis and hematology
- Trained in general laboratory management, quality assurance and control, legal issues, administration, data management, cost-benefit analysis, cost containment and human resource issues
- Assisted referring physicians with interpretation of laboratory results and decision-making to facilitate optimal patient management

AWARDS

- UNCF Merck Fellowship, 2004
- Honorable Mention, L'Oreal Women in Science Fellowship, 2004
- Johns Hopkins Dept of Pathology Young Investigator Day award, 2004
- Johns Hopkins Dept of Pathology Young Investigator Day award, 2003
- Adeoye Lambo Gold Medal for the Best Student In Psychiatry, 1992

PROFESSIONAL MEMBERSHIPS

- Society of Nuclear Medicine, Member, MI Industry Leaders Working Group
- Member, Quantitative Imaging Biomarkers Alliance
- Radiological Society of North America
- World Molecular Imaging Society, Member, Industry Board
- College of American Pathologists
- MITA, Member, MI Radiation Dose Task Force
- American MENSA Society

GENEBANK SUBMISSIONS

PATENTS

Pasternack GR, Adegbola O and the Johns Hopkins University School of Medicine. Control of proliferation

and apoptosis in cancer cells. US Provisional 11/413,082

INVITED PRESENTATIONS

2nd Annual Medical Device Investigator Initiated Trials Conference, September 27-28, 2012, Chicago, IL Strategies to Facilitate Translational Imaging in Drug Development, 2nd Imaging in Drug Development, January 23-24, 2008, London, UK

Exploratory Imaging in Drug Development - Cost Analysis and Resource Requirements, 5th Annual Medical Imaging for Clinical Trials, February 28-29, 2008, Arlington, VA

Imaging in Drug Development, Drug Discovery & Development of Innovative Therapeutics, August 4-7, 2008, Boston, MA

Translational Imaging in Drug Development, CHI 5th *In Vivo* Molecular Imaging, November 17-19, 2008, La Jolla, CA

Enhancing Imaging Techniques and Technologies to Streamline Drug Development, Translational Imaging in Drug Development, April 2-3, 2009, London, UK

ABSTRACTS AND PUBLICATIONS

- Adegbola, O and Conti P, Editors, "Molecular Imaging in Clinical Trials", Springer, due 2013
- M Bathaii, JR Saffer, PH Tang, J Karp, O Adegbola, L Loevner and A Alavi. Comparability of
 quantitative SUV measurement between PET alone and PET-CT on patients scanned consecutively
 on PET and PET-CT scanners. (SNM 2006 meeting)
- Adegbola O and Pasternack GR. Phosphorylated Rb complexes with pp32 and inhibits pp32-mediated apoptosis. (oral presentation, ASIP Experimental Biology 2005 meeting)
- Lee S, Huang M, Nelson D, Pickup S, Wehrli S, <u>Adegbola O</u>, Poptani H, Delikatny E, Glickson J. *In vivo* MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft. *NMR Biomed.* 2008 Aug; 21(7):723-33
- Adegbola O, Yang H, Zhuang H. Hepatobiliary scintigraphy monitoring patency of partial extent biliary diversion in a patient with progressive familial intrahepatic cholestasis. (cover) Clin Nucl Med. 2006 Oct; 31(10):622-623
- Adegbola O and Pasternack GR. A pp32 Rb complex modulates androgen receptor-dependent transcription and associates with components of the splicing machinery. Biochem Biophys Res Commi 2005 Aug 26;334(2):702-8
- Adegbola O and Pasternack GR. Phosphorylated Rb complexes with pp32 and inhibits pp32-mediated apoptosis. *J. Biol. Chem.* 2005 Apr; 280(16):15497-502
- Sahin F, Kannangai R, <u>Adegbola O</u>, Wang J, Su G, Torbenson M. mTOR and P70 S6 Kinase expression in Primary Liver Neoplasms. *Clin. Can. Res.* 2004 Dec; 10(24):8421-5
- Kannangai R, Sahin F, <u>Adegbola O</u>, Ashfaq R, Su GH, Torbenson M. *FHIT* mRNA and protein expression in hepatocellular carcinoma. *Mod. Pathol.* 2004 Jun;17(6):653-9



NetCE certifies that Onikepe Adegbola 045473 has participated in the enduring material titled #94130 Neck Pain in Adults on March 25, 2020 and is awarded 10 AMA PRA Category 1 Credit(s)™.

Treda S.O'Brien Erin K. Meiniger

Freda S. O'Brien

Erin K. Meinyer Executive Director

Director of Academic Affairs

In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center JOINTLY ACCREDITED PROVIDER (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.





NetCE certifies that Onikepe Adegbola MD438058 has participated in the enduring material titled #94130 Neck Pain in Adults on March 25, 2020 and is awarded 10 AMA PRA Category 1 Credit(s)™.

S.O'Brien Erin K. Meiniger Freda S. O'Brien

Director of Academic Affairs

Erin K. Meinver

Executive Director In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council

for Pharmacy Education (ACPE), and the American Nurses Credentialing Center JOINTLY ACCREDITED PROVIDER (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.





Certificate Completion

NetCE certifies that Onikepe Adegbola 045473 has participated in the enduring material titled #90781 Colorectal Cancer on March 25, 2020 and is awarded 15 AMA PRA Category 1 Credit(s)™.

Treda S.O'Brien Erin K. Meiniger

Freda S. O'Brien Director of Academic Affairs

Erin K. Meinyer Executive Director



In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center JOINTLY ACCREDITED PROVIDER" (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.





NetCE certifies that Onikepe Adegbola MD438058 has participated in the enduring material titled #90781 Colorectal Cancer on March 25, 2020 and is awarded 15 AMA PRA Category 1 Credit(s)™.

S.O'Brien Erin K. Meiniger Freda S. O'Brien

Director of Academic Affairs

Erin K. Meinyer Executive Director



In support of improving patient care, NetCE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center JOINTLY ACCREDITED PROVIDER" (ANCC), to provide continuing education for the healthcare team.

Florida CE Broker Provider #50-2405, Board of Medicine.



TO:

Connecticut Medical Examining Board

FROM:

Celeste Dowdell

Licensing Applications Analyst

Practitioner Licensing and Investigations Section

RE:

Sarita Mallya, MD

Dr. Mallya is an applicant for Connecticut physician licensure reinstatement. Dr. Mallya meets all requirements for reinstatement except she has been out of active practice since 2015.

Applicants who have been out of active clinical practice longer than six (6) months are reviewed by the Connecticut Medical Examining Board. The CMEB could require applicants who have been out of active clinical practice for longer than two years to complete the Federation of State Medical Board's Special Purpose Examination (SPEX).

Please accept this as a summary of the documentation submitted in support of Dr. Mallya's application.

Medical Education: Bangalore Medical College, India- 1996

United States Medical Licensing Examination: Parts 1-3 completed and passed

Post Graduate Training Completed:

07/01/00-06/30/02: Bergen Regional Medical Center, NJ- Psychiatry Resident

07/01/02-06/30/04: University of Connecticut Health Center- Psychiatry Resident

Dr. Mallya currently holds a license in California. There is no history of discipline against this license.

CT license issued 1/7/2004, expired 10/31/2010

Dr. Mallya is board certified in Psychiatry

Activities since License expired:

Statements attached

Re: Dr. Sarita Mallya; Statement

sn mn <smallya01@gmail.com>

Mon 8/24/2020 11:24 AM

To: Dowdell, Celeste < Celeste. Dowdell@ct.gov>

EXTERNAL EMAIL: This email originated from outside of the organization. Do not click any links or open any attachments unless you trust the sender and know the content is safe.

Good morning Ms. Dowdell, Hope things are well.

Circling back to check on the status of my application, whether it's been reviewed by Mr. Steven Garruthers (regret any spelling error), and a decision.

I'd also like to take this opportunity to highlight the fact that the very reason I am considering traveling cross-country during this deadly pandemic, even at the cost of being temporarily separated from my own family, is to serve the State of Connecticut and patients at Capitol Region Mental Health Center. I *love* Connecticut. I was professionally at home at CRMHC, and wouldn't have left had it not been for the family move to California. I understand the severely and persistently mentally ill population that CRMHC serves, and find working with this group very rewarding. Deciding between diagnostic intricacies, prescribing and monitoring multiple potent psychotropic medications, obtaining necessary lab work, referring patients for general medical or other specialty follow up as needed, coordinating between various available community services, taking care of emergencies...I managed it all without an issue. In voluntarily taking after-hours calls, I was once even part of a SWAT Team assessing a patient out in the community who had made a threat to a public official. I am experienced and very familiar with the challenges involved in working with State patients. Additionally, I got along seamlessly with my team at CRMHC; I know and fully assimilated with their work culture.

I ask that in addition to my statement provided, the above facts are considered, and also that to date, I have a clean medico-legal record.

I am hopeful for a favorable outcome of the review and await a timely response.

Respectfully,

Sarita Mallya, M.D.

On Fri, Aug 21, 2020 at 4:25 AM Dowdell, Celeste < Celeste. Dowdell@ct.gov > wrote:

Thank you

To Whom It May Concern in the Department of Public Health. State of CT

Hello.

This is Dr. Sarita Mallya. I graduated from the University of Connecticut Health Center's Residency Program in Psychiatry in 2004. As a Psychiatrist in CT, I worked in the Institute of Living, then in Waterbury Hospital, and the longest with the State of Connecticut's Department of Mental Health and Addiction Services at Capitol Region Mental Health Center in Hartford, before a family move to California.

I since worked for different organizations until I was the victim in a horrific multi-vehicle crash on the highway in 2015, initiated by a truck driver on his cellphone. It caused a variety of unforeseen, hard-to-manage problems, necessitating I focus on medically recovering. Sadly, just as I was getting better in late 2018 to look into rejoining the workforce, I was the victim in another traumatic accident: T-boned at high speed by an elderly driver on a dark January evening in 2019. It took me a year to get back on my feet and begin looking for work earlier this year, just as Covid descended. I unfortunately have no nice tales to tell about the recklessly aggressive, constant LA traffic; it has to be survived to be talked about.

I have always been a stellar student, not just in my schooling years but beyond. I consistently won extremely competitive annual national scholarships from the Government of India, and ranked very high in India in each of the medical-entrance exams I took, including an all-India 2nd in the prestigious Armed Forces Medical College exam. After medical school, I passed each of the 3 steps of the USMLE in a single attempt, as also the TOEFL/Test of English as a Foreign Language, with a perfect score to boot. (Having always enjoyed the English language and being an avid reader, writer, and published author helped).

In Residency, even in 1st year, I consistently scored among the top 2 or 3 in the annual national Psychiatry Residents Exams, in the whole group of PGY-1 through 4s. As a PGY4 at UConn, I was the rotating Chief Resident of Inpatient Services, and nominated by Dr. Joyce Tinsley, then the Residency Training Program Director, to attend the American Psychiatric Association with Eli Lilly's Executive Leadership Program in Boston in 2003. As a result of being academically curious and clinically astute, I also achieved Board-Certification in Psychiatry in my first attempt in 2005 from the American Board of Psychiatry and Neurology.

I have always enjoyed learning. I routinely accrue more CMEs than required. For example, even while suffering for years as a result of the accidents, I would seek online CME activities to keep abreast with not just Psychiatry but routine issues in Medicine. I have always maintained my California medical license - which has the notoriety of being



July 27, 2020

Connecticut Medical Examining Board
Oplc.dph@ct.gov
PO Box 340308
Hartford, CT 06134-0308

RE: Sarita Mallya, MD - DOB: 10/18/1972

To Whom It May Concern:

In response to your request for affiliation verification, we are able to provide the following information:

Practitioner:

Sarita Mallya, MD

Title:

Independent Contractor - Staff Psychiatrist

Status:

Inactive

Specialty:

Psychiatry

Initial Date:

11/16/2014 through 06/14/2015

The above-named practitioner works(ed) under contract through TBH providing inpatient and/or outpatient psychiatric services to our facility clients including the following:

Telecare Corporation Orange – Santa Ana, CA

Dr. Mallya was a member in good standing with Traditions Behavioral Health. There is nothing of a derogatory nature in the file that would reflect adversely on this individual's professional standing or personal character.

Should you have any questions or need additional information, please do not hesitate to contact the credentialing office.

Sincerely,

Cissy Broadwell

Credentials Coordinator

(707) 258-8757

Cissy@tbhcare.com

Sarita Mallya, M.D. smallya01@gmail.com

LICENSURE AND CERTIFICATION

Valid California physician license since July 2010; current through 10/31/2021.

Valid Federal DEA registration; current through January 2022.

Board Certified in Psychiatry by the American Board of Psychiatry and Neurology in first attempt, April 2005.

Licensed to practice Medicine in Connecticut since January 2004.

ECFMG Certified, indefinitely.

Between March 1998 - July 1999: Passed the USMLE (United States Medical Licensing Examination) 1, 2 and 3; and the TOEFL (Test Of English as a Foreign Language) with a perfect score; each in a single attempt.

Licensed to practice Medicine in India by the Karnataka Medical Council since May 1997.

EDUCATION

July 2000 to June 2004: Residency in Psychiatry. PGY 1, 2: Bergen Regional Medical Center, Paramus, NJ. PGY 3, 4: University of Connecticut Health Center, Farmington, CT.

May 1996 to May 1997: Comprehensive medical/surgical internship, Bangalore, India.

August 1991 to February 1996: Bangalore Medical College, Bangalore, India.

CLINICAL EXPERIENCE

October 2014 through June 2015: Psychiatrist, Telecare, Santa Ana, CA

April to July 2012: Psychiatrist, Kaiser Permanente, Sherman Oaks and Santa Clarita, CA

August to December 2011: Psychiatrist, Pacific Clinics, Los Angeles, CA

October 2006 to May 2010: Principal Psychiatrist, Capitol Region Mental Health Center,

Department of Mental Health and Addiction Services, Hartford, CT

October 2005 to June 2006: Attending Psychiatrist, Adult Outpatient and Intensive Outpatient

Services; Waterbury Hospital, Waterbury, CT

July 2004 to October 2005: Attending Psychiatrist, Intensive Outpatient Program for

Professionals, and the Adult Partial Hospital Program; Institute of Living, Hartford Hospital,

Hartford, CT.

Responsible for diagnostic evaluation; managing psychopharmacological agents; brief/problem-focused therapy for individuals, couples, and groups; treatment planning with multidisciplinary teams. Served patients with a wide range of psychiatric disorders; many with concomitant substance-use. In NJ, administered buprenorphine for opioid dependence. Experienced in the Clozaril protocol. Worked with patients ranging in age from late teens to the geriatric population, of varied socioeconomic, ethnic, and cultural backgrounds. Effective in leadership and collaborative roles. Experienced in the Recovery model: treatment occurring in partnership with the patient. While at the Capitol Region Mental Health Center and at the Institute of Living: in taking calls after-hours, weekends and holidays, experienced in managing hospitalized patients, crisis evaluations, community outreach/ACT model, coordinating available staff and services including emergency personnel.

July 1999 to April 2000: Research assistant in Pathological Gambling, Department of Psychiatry, University of Connecticut Health Center. Recruited patients, conducted interviews with patients and collaterals, administered structured psychiatric interviews, entered data. Principal Investigator: Nancy Petry, Ph.D.

June 1999 to July 1999: Scaife Fellowship Program in Addiction Services, St. Francis Medical Center, Pittsburgh, PA. Participated in psychiatric and substance abuse programs in hospital and community centers, researched and developed a proposal to better coordinate services. Supervisor: Janice Pringle, Ph.D.

November 1998 to April 2000: Organized and attended sixteen psychotherapy workshops as part of the University of Connecticut Master Therapists program; participated in team meetings at the Partial Hospital Program.

October 1998 to December 1998: Volunteer in Consultation-Liaison Psychiatry, University of Connecticut. Participated in assessment and treatment of outpatients and hospital consults. Supervisor: Henry Weisman, M.D.

May 1996 to May 1997: Internship at the Victoria, Vani Vilas, and Bowring Hospitals, Bangalore, India. Provided emergency, outpatient, community outreach, and continuing inpatient care; supervised by attending physicians.

AWARDS AND HONORS

October 2003: Nominated by Dr. Joyce Tinsley, Psychiatry residency training director at the University of Connecticut, to attend the APA-Lilly Chief Residents' Executive Leadership Program, Institute of Psychiatric Services, Boston, MA.

June 2003: Excellence in Scholarship award, Department of Psychiatry, University of Connecticut.

October 2002: New Jersey Psychiatric Association honorable mention for best paper--Psychosis and Violence in a hospital Forensic Psychiatry service.

June 2002: Certificate of commendation for excellent service, Bergen Regional Medical Center. November 2001: Nominated as an outstanding resident by Dr. Javed Iqbal, Psychiatry residency training director at Bergen Regional Medical Center, to attend the Psychiatric Congress, Boston, MA.

1991: Ranked 2ndin India in the prestigious Armed Forces Medical College entrance exam. 1988-1996: After 3 rounds of qualifying exams and an interview, awarded a highly competitive annual scholarship by the National Council of Educational Research and Training, India. 1986-1996: Received an annual scholarship from the Government of India for outstanding academic performance.

CONTINUING MEDICAL EDUCATION

2011 to date: Psychiatry Grand Rounds and specialized workshops at the University of California, Los Angeles. Medical and Addiction conferences at the Torrance Memorial Hospital, Torrance, CA. Pri-Med online CME.

May 2019: UCLA Cannabis Research Symposium

September 2014: ER/LA opioid analgesics risk management and mitigation strategies course. August 2013: Pain Management/End of Life Care course (required by the CA Medical Board).

November 5, 2011: UCLA Annual Review of Psychiatry.

October 2011: Institute of Psychiatric Services, APA, San Francisco, CA.

April 2010: American Academy of Clinical Psychiatrists, Chicago, IL.

April 2009: Pri-Med Conference, Hartford, CT.

October 2007: Pri-Med Conference, Boston, MA.

February 2006: University of Arizona Psychopharmacology Review, Tucson, AZ.

March 2005: Diagnostic Interviewing course, Harvard Medical School, MA.

October 2004: Clinical Neurology for Psychiatrists course, New York, NY.

May 2004: American Psychiatric Association meeting, New York, NY.

July 1998 to June 2000: Attended weekly Grand Rounds in the Departments of Psychiatry and

Internal Medicine, and seminars on Law, Ethics and Managed Care.

LEADERSHIP, TEACHING AND COMMUNITY SERVICE

August 2007 to Jan 2014: Volunteered and worked in public elementary schools.

July 2003 to October 2005: Taught Psychiatry to medical students and residents at the University of Connecticut and at the Institute of Living.

February to March 2004: Inpatient Chief Resident in Psychiatry, University of Connecticut.

February to March 2004: Volunteered at Hartford Behavioral Health, a community clinic providing ongoing evaluation and medication management for outpatients.

SCIENTIFIC PUBLICATIONS AND POSTERS

Petry N.M. and Mallya S. Gambling participation and problems among employees at a university health center. J Gambl Stud. 2004; 20:155-70.

Mallya, Sarita and Lewis, Catherine. Gender, psychosis and violence in a forensic psychiatry service. Presented April 2003 at the University of Connecticut Health Center Department of Psychiatry's Annual Research Day.

primed




CONN	E	CT	E	D	L	E	A	R	١	-	N	J	G	
------	---	----	---	---	---	---	---	---	---	---	---	---	---	--



Date Description

My Credits



07/12/2020

COVID-19 and Seniors: What Happened in I Homes and How Can We Fix It? (Recorded 05/18/2020) Podcast

07/12/2020

COVID-19 Web Series Part 5: A Shift to Virt Care

Virtual CME Program


07/12/2020

Frankly Speaking Update: COVID-19 and Speaking Update: COVID-19 an

Podcast

Legend





State License CME/CE Requirements for Physicians, Nurse Practitioners, and Physician Assistants	07/12/2020	Getting to Remission—Not Just Better: Can a Web-Based CBT Tool Help Resolve Residual Depressive Symptoms in People Treated for Depression? - Frankly Speaking EP 176 Podcast
The following links are provided as a resource for your state CME/CE license		
requirements. Please verify all information with your state licensing agency.	07/12/2020	Weight Loss Best Evidence 2020 Virtual CME Program
Physicians		
Physician Assistants		
Nurse Practitioners	07/10/2020	Improving Communication Between Parents and Teens - Frankly Speaking EP 153
		Podcast
	07/10/2020	Statins After 75 Years of Age in Healthy Senior Still No - Frankly Speaking EP 137
		Podcast







Drastitionare contact have







The following links are provided as a resource for your state CME/CE license requirements. Please verify all information with your state licensing	10/16/2019	Case Study: Persistent Symptoms of Shortne Breath in a Longtime Smoker Patient Case Study
agency.		
Physicians		
Physician Assistants	10/16/2019	Avoiding Unnecessary Antibiotics: The Quick - Frankly Speaking EP 118
Nurse Practitioners		Podcast
	10/16/2019	A Brief Overview of Common Challenges to Diagnosis and Management of COPD: Freque Asked Questions
		Expert Perspective
	10/16/2019	Update in Adolescent Care (Recorded at Pri-I Southwest)
		Webcast











rilysician Assistants		
The following links are provided as a resource for your state CME/CE license requirements. Please verify all information with your state licensing agency.	10/13/2019	Case Example: Treatment of Influenza in Adults Patient Case Study
Physicians		
Physician Assistants	10/13/2019	Cases: Clinical Pearls for Managing Influenza in Children
Nurse Practitioners		Patient Case Study
	10/13/2019	Expert Perspective: The Essentials of Identifying Candidates and Treating Influenza in the Outpatient Setting
		Expert Perspective
	10/13/2019	Current Concepts in the Management of Influer What You Should Know to Reduce the Burden of Disease
		Virtual CME Program

STATE OF CONNECTICUT DEPARTMENT OF PUBLIC HEALTH HEALTHCARE QUALITY AND SAFETY BRANCH

Bryan Boffi, M.D. Petition No.: 2016-1045

BIOGRAPHICAL INFORMATION:

Medical School: Brown University

Year of Graduation: 1982

Post Graduate Training:

6/1/1983 - 6/1/1984 Intern Miriam Hospital, Providence, Rhode Island

7/1/1985 - 6/30/1988 Resident Cornell University Medical College, New York, NY 7/1/1988 - 6/30/1989 Fellowship Cornell University Medical College, New York, NY

Current Employment: Hospital of Central CT, New Britain, CT

License Issued: 4/7/1989
Type of Practice: Psychiatry
Malpractice History: None Reported
Past History with DPH: None Reported

THIS CONSENT ORDER DISCIPLINE:

- Reprimand
- \$5000.00 Civil Penalty

DEPARTMENT SUMMARY:

In August, 2016 the Department's Practitioner Licensing and Investigations Section opened this petition in response to a complaint from the patient's family member.

Respondent provided care to Patient#1 between May 10, 2016 and May 19, 2016, during the patient's inpatient psychiatric admission to the Hospital of Central Connecticut ("HOCC"). The Department alleges that respondent failed to contact Patient #1's psychiatrist to discuss Patient #1's history and inpatient treatment strategy, and respondent inappropriately prescribed 90 Ativan 1 mg tablets to Patient #1 upon his discharge from HOCC.

WILL THIS RESULT IN A REPORT TO THE NPDB? Yes.

STATE OF CONNECTICUT DEPARTMENT OF PUBLIC HEALTH HEALTHCARE QUALITY AND SAFETY BRANCH

In re: Bryan Boffi, M.D.

Petition No.: 2016-1045

CONSENT ORDER

WHEREAS, Bryan Boffi of Avon, Connecticut (hereinafter "respondent") has been issued license number 029834 to practice medicine and surgery by the Department of Public Health (hereinafter "the Department") pursuant to Chapter 370 of the General Statutes of Connecticut, as amended; and,

WHEREAS, the Department alleges that:

- 1. Respondent provided care to Patient #1 between approximately May 10, 2016 and May 19, 2016, during the patient's inpatient psychiatric admission to the Hospital of Central Connecticut ("HOCC"). Respondent's care for Patient #1 failed to meet the standard of care in one or more of the following ways:
 - Respondent failed to contact Patient #1's outpatient psychiatrist to discuss Patient #1's history
 and inpatient treatment strategy; and/or
 - b. Respondent inappropriately prescribed 90 Ativan 1 mg tablets to Patient #1 upon his discharge from HOCC.
- 2. The above-described facts if proven constitute grounds for disciplinary action pursuant to the General Statutes of Connecticut, §20-13c, including but not limited to §20-13c(4).

WHEREAS, respondent, in consideration of this Consent Order, while admitting no guilt or wrongdoing and expressly denying any guilt or wrongdoing, has chosen not to contest the above allegations, and agrees that for purposes of this or any future proceedings before the Connecticut Medical Examining Board (hereinafter "the Board"), this Consent Order shall have the same effect as if proven and ordered after a full hearing held pursuant to §§19a-10, 19a-14 and 20-13c of the General Statutes of Connecticut.

WHEREAS, respondent has successfully completed over 150 hours of continuing education related to depression, prescribing of benzodiazepines, addiction and documentation standards, including the following courses: The Role of Benzodiazepines in the Elderly; The Role of Benzodiazepines in the Treatment of Anxiety; Issues in Benzodiazepine

Pharmacology; Benzodiazepines and the Aging Brain; Psychopharmacology in Neuropsychiatry; Withdrawal Syndromes and Management of Opioids, Benzodiazepines and Cannabinoids; Understanding Addiction; Ethical, Legal and Forensic Issues in Geriatric Psychiatry; Substance Abuse in Patients with Depression; Risk Management Focus:

Communication among Colleagues; and Risk Management Essentials: Documentation,

WHEREAS, a random audit of respondent's charts at the Hospital of Central Connecticut performed over a two-year period between 2016 and 2018 confirmed that Patient #1 was the only patient prescribed 90 benzodiazepines by respondent at the time of discharge.

NOW THEREFORE, pursuant to §§19a-14, 19a-17 and 20-13c of the General Statutes of

- 1. Respondent waives his right to a hearing on the merits of this matter.
- Respondent's license number 029834 to practice medicine and surgery in the State of Connecticut is hereby reprimanded.
- 3. Respondent shall pay a civil penalty of five thousand dollars (\$5,000.00) by certified or cashier's check payable to "Treasurer, State of Connecticut." The check shall reference the Petition Number on the face of the check, and shall be payable at the time respondent submits the executed Consent Order to the Department.
- Respondent shall comply with all state and federal statutes and regulations applicable to his licensure.
- 5. This Consent Order is effective on the first day of the month immediately following the date this Consent Order is accepted and ordered by the Board.
- 6. Respondent understands and agrees that this Consent Order shall be deemed a public document, and the Department's allegations as contained in this Consent Order shall be deemed true in any subsequent proceeding before the Board in which his compliance with this Consent Order or with §20-13c of the General Statutes of Connecticut, as amended, is at issue. Further, respondent understands that any discipline imposed by this Consent Order shall be reported to the National Practitioner Data Bank maintained by the United States Department of Health and Human Services, and that all disciplinary actions will appear on his physician profile pursuant to Connecticut General Statutes 20-13j.
 - 7. This Consent Order and terms set forth herein are not subject to reconsideration, collateral attack or judicial review under any form or in any forum. Respondent agrees that this Consent Order shall not be subject to modification as a result of any claim that the terms contained herein may result in action by third parties, including, but not limited to,

healthcare facilities and/or credentialing or licensure boards and respondent waives any right to seek reconsideration or modification of this Consent Order pursuant to §4-181a of the General Statutes of Connecticut. Respondent assumes all responsibility for assessing such actions prior to the execution of this document. Further, this Consent Order is not subject to appeal or review under the provisions of Chapters 54 or 368a of the General Statutes of Connecticut, provided that this stipulation shall not deprive respondent of any rights that he may have under the laws of the State of Connecticut or of the United States.

- 8. This Consent Order is a revocable offer of settlement which may be modified by mutual agreement or withdrawn by the Department at any time prior to its being executed by the last signatory.
 - Respondent permits a representative of the Department to present this Consent Order and the factual basis for this Consent Order to the Board. Respondent understands that the Board has complete and final discretion as to whether this executed Consent Order is approved or accepted. Respondent hereby waives any claim of error that could be raised that is related to or arises during the course of the Board's discussions regarding whether to approve or reject this Consent Order and/or a Board member's participation during this process, through the Board member's review or comments, including but not limited to bias or reliance on evidence outside the administrative record if this matter proceeds to a hearing on a statement of charges resulting in a proposed decision by the Board and/or a panel of the Board and a final decision by the Board.
- 10. Respondent has the right to consult with an attorney prior to signing this document.
- 11. The execution of this document has no bearing on any criminal liability without the written consent of the Director of the Medicaid Fraud Control Unit or the State's

the Chief State's Attorney's Office. The purpose of this Consent Order is to resolve the pending administrative license disciplinary petition only, and is not intended to affect any civil or criminal liability or defense.

12. This Consent Order embodies the entire agreement of the parties with respect to this case.

All previous communications or agreements regarding the subject matter of this consent order, whether oral or written, between the parties are superseded unless expressly incorporated herein or made a part hereof.

2

I, Bryan Boffi, have read the above Consent Order, and I stipulate and agree to the terms as set	
forth therein. I further declare the execution of this Consent Order to be my free act and deed.	
Bryan Boffi, M.D.	
ah 2	
Subscribed and sworn to before me this day of day of 2020.	
thlacer Fisher Pilson	
Notary Public or person authorized	
by law to administer an oath or affirmation	
The above Consent Order having been presented to the duly appointed agent of the	
a m	
Commissioner of the Department of Public Health on the 232 day of	
— July 2020, it is hereby accepted. (Muttan Mandum	
Christian D. Andresen, MPH, Section Chief	
Practitioner Licensing and Investigations Section Healthcare Quality and Safety Branch	
And the second s	
The above Consent Order having been presented to the duly appointed agent of the Connecticut	
Medical Examining Board on the day of 2020, it is	
hereby ordered and accepted.	
Connecticut Medical Examining Board	

CONNECTICUT MEDICAL EXAMINING BOARD CONSENT ORDER COVER SHEET

Respondent: Glen S. Rosenfeld, M.D. Petition No. 2019-44

BIOGRAPHICAL INFORMATION:

Medical School: New York University School of Medicine

Year of Graduation: 1991

07/01/1991-06/30/1992 Internal Intern Sinai Hospital, Baltimore, MD

Medicine

07/01/1992-06/30/1995 Anesthesiology Resident John's Hopkins Medical Institute,

Baltimore, MD

Current employment: Unknown

License: 041323 Issued: 4/4/2003

Type of Practice: Anesthesiology

Board Certification: American Board of Anesthesiology

Malpractice History: November 2008 (Average) and May 2013 (Below Average)

Past History with DPH: None

Investigation Commenced: 1/16/2019

THIS CONSENT ORDER DISCIPLINE:

Civil Penalty of Five Thousand Dollars (\$5,000.00)

DEPARTMENT SUMMARY OF THE CASE:

- The Department's Facility Licensing and Investigations Section (FLIS) made a referral to the Department's Practitioner Licensing and Investigations Section (PLIS) after a FLIS investigation determined that respondent performed an eye block and a femoral block on the wrong site.
- Respondent admits that in October 2016 he performed a retro bulbar block on the wrong eye of a patient and that in November 2017 he performed a pre-operative femoral nerve block on the wrong side of a patient. Both errors were discovered prior to surgery.
- The discipline in this Consent Order is consistent with prior order of the Connecticut Medical Examining Board for similar conduct.

WILL THIS RESULT IN A REPORT TO THE N.P.D.B. BANK?

Yes

STATE OF CONNECTICUT
DEPARTMENT OF PUBLIC HEALTH
HEALTHCARE QUALITY AND SAFETY BRANCH

In re: Glen S. Rosenfeld, M.D.

Petition No. 2019-44

CONSENT ORDER

WHEREAS, Glen S. Rosenfeld of West Hartford, Connecticut (hereinafter "respondent") has been issued license number 041323 to practice as a physician and surgeon by the Department of Public Health (hereinafter "the Department") pursuant to Chapter 370 of the General Statutes of Connecticut, as amended; and,

WHEREAS, respondent admits that:

- 1. On or about October 18, 2016, respondent performed a retro bulbar block on the wrong eye of patient #1; and
- On or about November 29, 2017, respondent performed a pre-operative femoral nerve block on the wrong side of patient #2.
- 3. The above described facts constitute grounds for disciplinary action pursuant to the General Statutes of Connecticut, §20-13c, including, but not limited to §20-13c(4).

WHEREAS, respondent, in consideration of this Consent Order, has chosen not to contest this matter and/or whether disciplinary action is warranted in this matter and agrees that for purposes of this or any future proceedings before the Connecticut Medical Examining Board (hereinafter "the Board"), this Consent Order shall have the same effect as if proven and ordered after a full hearing held pursuant to §§19a-10, 19a-14 and 20-13c of the General Statutes of Connecticut.

NOW THEREFORE, pursuant to §§19a-14, 19a-17 and 20-13c of the General Statutes of Connecticut, respondent hereby stipulates and agrees to the following:

- 1. Respondent waives respondent's right to a hearing on the merits of this matter.
- 2. Respondent shall pay a civil penalty of five thousand dollars (\$5,000.00) by certified or cashier's check payable to "Treasurer, State of Connecticut." The check shall reference the Petition Number on the face of the check, and shall be payable at the time respondent submits the executed Consent Order to the Department.
- 3. Respondent shall comply with all state and federal statutes and regulations applicable to respondent's licensure.
- 4. Respondent shall pay all costs necessary to comply with this Consent Order.
- 5. Legal notice shall be sufficient if sent to respondent's last known address of record reported to the Practitioner Licensing and Investigations Section of the Healthcare Quality and Safety Branch of the Department.
- 6. This Consent Order is effective on the date this Consent Order is accepted and ordered by the Board.
- 7. Respondent understands and agrees that this Consent Order shall be deemed a public document and the above admitted violations shall be deemed true in any proceeding before the Board in which respondent's compliance with this Consent Order or with Chapter 370 of the General Statutes of Connecticut, as amended, is at issue. Further, respondent understands that any discipline imposed by this Consent Order shall be reported to the National Practitioner Data Bank maintained by the United States Department of Health and Human Services and that all disciplinary actions will appear on respondent's physician profile pursuant to Connecticut General Statutes 20-13j.

- This Consent Order and terms set forth herein are not subject to reconsideration, collateral attack or judicial review under any form or in any forum. Respondent agrees that this Consent Order shall not be subject to modification as a result of any claim that the terms contained herein may result in action by third parties, including, but not limited to, healthcare facilities and/or credentialing or licensure boards and respondent waives any right to seek reconsideration or modification of this Consent Order pursuant to §4-181a of the General Statutes of Connecticut without the express consent and agreement of the Department. Respondent assumes all responsibility for assessing such actions prior to the execution of this document. Further, this Consent Order is not subject to appeal or review under the provisions of Chapters 54 or 368a of the General Statutes of Connecticut, provided that this stipulation shall not deprive respondent of any rights that respondent may have under the laws of the State of Connecticut or of the United States.
- 9. This Consent Order is a revocable offer of settlement which may be modified by mutual agreement or withdrawn by the Department at any time prior to its being executed by the last signatory.
- 10. Respondent permits a representative of the Department to present this Consent Order and the factual basis for this Consent Order to the Board. Respondent understands that the Board has complete and final discretion as to whether this executed Consent Order is approved or accepted. Respondent hereby waives any claim of error that could be raised that is related to or arises during the course of the Board's discussions regarding whether to approve or reject this Consent Order and/or a Board member's participation during this process, through the Board member's review or comments, including but not limited to bias or reliance on evidence outside the administrative record if this matter proceeds to a hearing on a statement of charges resulting in a proposed decision by the Board and/or a panel of the Board and a final decision by the Board.

- 11. Respondent has the right to consult with an attorney prior to signing this document.
- 12. The execution of this document has no bearing on any criminal liability without the written consent of the Director of the Medicaid Fraud Control Unit or the State's Attorney's Office where the allegation occurred or Bureau Chief of the applicable unit in the Chief State's Attorney's Office. The purpose of this Consent Order is to resolve the pending administrative license disciplinary petition only, and is not intended to affect any civil or criminal liability or defense.
- 13. This Consent Order embodies the entire agreement of the parties with respect to this case.

 All previous communications or agreements regarding the subject matter of this consent order, whether oral or written, between the parties are superseded unless expressly incorporated herein or made a part hereof.

×

V.

34

I, Glen S. Rosenfeld, have read the ab	ove Consent Order, and I stipulate and agree to the terms
as set forth therein. I further declare t	he execution of this Consent Order to be my free act and
deed.	
	Glen S. Rosenfeld, M.D.
Subscribed and sworn to before me th	Notary Public or person authorized by law to administer an oath or affirmation
Commissioner of the Department of P	represented to the duly appointed agent of the Public Health on the day of ereby accepted. Christian D. Andresen, MPH, Section Chief Practitioner Licensing and Investigations Section Healthcare Quality and Safety Branch
	n presented to the duly appointed agent of the
	Connecticut Medical Examining Board